aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
02. Oktober 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
22. Juli 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
14. März 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
18. Januar 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
13. September 2022 08:00 ET
|
aTyr Pharma, Inc.
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE)...
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
30. August 2022 08:00 ET
|
APIE Therapeutics
CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...
Interstitial Lung Disease Clinical Trial Pipeline Insights | DelveInsight
22. Juni 2022 12:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, June 22, 2022 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Clinical Trial Pipeline Insights | DelveInsight Interstitial lung disease Pipeline involves 120+ key companies...
Steering committee of pulmonary and primary care experts aims to reduce time to diagnose complex lung diseases
17. Mai 2022 10:00 ET
|
American College of Chest Physicians
GLENVIEW, Ill., May 17, 2022 (GLOBE NEWSWIRE) -- The American College of Chest Physicians (CHEST) and Three Lakes Foundation are announcing a steering committee of experts in the fields of pulmonary...
Global Interstitial Lung Disease Market to Surpass US$ 2453.5 Million by 2028, Says Coherent Market Insights (CMI)
27. Dezember 2021 08:30 ET
|
CMI
SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global interstitial lung disease market is estimated to be valued at US$ 1578.9 million in 2021 and is expected...
aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
14. August 2018 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...